Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals

Individuals on immunosuppressive (IS) therapy have increased mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and delayed viral clearance may lead to new viral variants. IS therapy reduces antibody responses following coronavirus disease 2019 (COVID-19) messenge...

Descripción completa

Detalles Bibliográficos
Autores principales: Collier, Ai-ris Y, Yu, Jingyou, McMahan, Katherine, Liu, Jinyan, Atyeo, Caroline, Ansel, Jessica L, Fricker, Zachary P, Pavlakis, Martha, Curry, Michael P, Jacob-Dolan, Catherine, Patel, Het, Sellers, Daniel, Barrett, Julia, Rowe, Marjorie, Ahmad, Kunza, Gompers, Annika, Aguayo, Ricardo, Chandrashekar, Abishek, Alter, Galit, Hacker, Michele R, Barouch, Dan H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690024/
https://www.ncbi.nlm.nih.gov/pubmed/34792136
http://dx.doi.org/10.1093/infdis/jiab569
Descripción
Sumario:Individuals on immunosuppressive (IS) therapy have increased mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and delayed viral clearance may lead to new viral variants. IS therapy reduces antibody responses following coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccination; however, a comprehensive assessment of vaccine immunogenicity is lacking. Here we show that IS therapy reduced neutralizing, binding, and nonneutralizing antibody functions in addition to CD4 and CD8 T-cell interferon-γ responses following COVID-19 mRNA vaccination compared to immunocompetent individuals. Moreover, IS therapy reduced cross-reactivity against SARS-CoV-2 variants. These data suggest that the standard COVID-19 mRNA vaccine regimens will likely not provide optimal protection in immunocompromised individuals.

Ejemplares similares